GlassScriptPhysician profile
Clint N Wilson
NPI 1427269059
$15,603.00
in general payments reported to CMS, 2019-2025
56 companies · $1,849 in 2025
The $1,849 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,337 · 2020: $1,924 · 2021: $2,143 · 2022: $2,267 · 2023: $2,168 · 2024: $1,915 · 2025: $1,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,887 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,887.09 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,408.88 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Allergan, INC. | $2,239.90 | 2019-2020 | |
| Lilly USA, LLC | $1,611.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,297.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $978.86 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $968.44 | 2019-2025 | |
| Amgen INC. | $723.35 | 2019-2025 | Evenity, Otezla, Enbrel |
| Takeda Pharmaceuticals U.S.A., INC. | $632.18 | 2020-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $521.41 | 2019-2023 | Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $463.99 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $382.25 | 2019-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.56 | 2019-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $369.62 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $208.48 | 2022 | |
| Inspire Medical Systems, INC. | $201.83 | 2023-2025 | Inspire |
Show all 55 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clint Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.